Gastroenterology Review
eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
Original paper

One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure

Shimaa Kamel
1
,
Waleed Hamed Abd Alaty
1
,
Heba Rashad
1
,
Dina Fathy
1
,
Mohamed Abdel-Samiee
2
,
Ibrahim Hindy
1
,
Ahmed Shaban
2
,
Safaa Askar
1

  1. Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Abbasiya Square, Cairo, Egypt
  2. Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt
Gastroenterology Rev
DOI: https://doi.org/10.5114/pg.2025.156473
Online publish date: 2025/11/27
Article file
- One-year single.pdf  [0.10 MB]
Get citation
 
PlumX metrics:
 
1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet 2017; 389: 1741-55.
2. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet 2017; 389: 1756-70.
3. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 2017; 152: 351-61.e355.
4. Gionchetti P, Dignass A, Danese S, et al. 3rd European Evidence-based Consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: surgical management and special situations. J Crohns Colitis 2017; 11: 135-49.
5. Sochal M, Krzywdzińska M, Gabryelska A, et al. A simple index to predict the efficiency of adalimumab treatment in Crohn disease with a limited duration of therapy. Pol Arch Intern Med 2020; 130: 910-2.
6. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther 2014; 39: 1349-62.
7. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 447-59.
8. Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41: 613-23.
9. Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis 2020; 14: 694-709.
10. Atreya R, Neurath MF, Siegmund B. Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to Anti-TNF? Front Med 2020; 7: 517.
11. Gisbert JP, Chaparro M. Ustekinumab to treat Crohn’s disease. Gastroenterol Hepatol 2017; 40: 688-98.
12. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-21.
13. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016; 375: 1946-60.
14. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res 2018; 16: 26-42.
15. Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis 2015; 21: 1151-9.
16. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7.
17. Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther 2018; 47: 896-905.
18. Engel T, Yung DE, Ma C, et al. Effectiveness and safety of ustekinumab for Crohn’s disease; systematic review and pooled analysis of real-world evidence. Dig Liver Dis 2019; 51: 1232-40.
19. Rayer C, Nachury M, Bourreille A, et al. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study. BMC Gastroenterol 2022; 22: 498.
20. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
21. Freeman HJ. Colorectal cancer risk in Crohn’s disease. World J Gastroenterol 2008; 14: 1810-1.
22. Ali El-Nady M, El-Hefny N, Fathy H, et al. The role of intestinal ultrasound with colour Doppler in predicting the response to biologic therapy in inflammatory bowel disease patients. Gastroenterol Rev 2024; 19: 416-22.
23. Kamel S, Sakr M, Hamed W, et al. Comparative study between bowel ultrasound and magnetic resonance enterography among Egyptian inflammatory bowel disease patients. World J Gastroenterol 2020; 26: 5884-95.
24. Askar SR, Amin A, Hagag RS, et al. Outcome of ulcerative colitis patients after one year of biological therapy in selected Egyptian patients. J Egypt Soc Parasitol 2022; 52: 279-86.
25. Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther 2020; 52: 1341-52.
26. Rayer C, Nachury M, Bourreille A, et al. Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study. BMC Gastroenterol 2023; 23: 31.
27. Ollech JE, Dwadasi S, Rai V, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020; 51: 637-43.
28. Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther 2020; 52: 123-34.
29. Hyun HK, Zhang HS, Yu J, et al. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol 2022; 22: 143.
30. Alric H, Amiot A, Kirchgesner J, et al. DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: a multi-centre comparative study. J Crohn’s Colitis 2020; 14: S118-20.
31. Biemans V, van der Woude C, van der Meulen- de Jong A, et al. DOP052 Vedolizumab vs. ustekinumab for Crohn’s disease: comparative effectiveness in a real-life observational cohort study (ICC case series). J Crohn’s Colitis 2018; 12: S066-7.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.